Podcasts about car t cell

Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year. We're also talking about next-generation CAR T-cell therapy for MS, and we'll explain why it's such exciting news. We're sharing details about a DNA-based therapy for overactive bladder that just received fast-track status from the FDA. We'll tell you about a new effort to develop a simple blood test that will detect MS progression. We have some news to share about the RealTalk MS app. And we want to remind you to check out our ECTRIMS Extra Conversations video playlist on the RealTalk MS YouTube channel! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A deep dive into the research presented at ECTRIMS 2025  :22 Kernal Biologics received $48 million grant for the next-generation CAR T-Cell therapy  2:35 FDA grants fast track designation to DNA-based therapy to treat overactive bladder  6:02 Octave Bioscience receives grant to develop a blood test to detect MS progression  8:30 News about our app  9:42 Have you checked out our ECTRIMS Extra Conversations YouTube playlist?  10:30 Dr. Bruce Bebo discusses some of the most important research presented at ECTRIMS 2025  11:06 Share this episode  32:26 Next week's episode  32:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/425 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy LISTEN: RealTalk MS Ep 422: From ECTRIMS 2025 with Dr. Bruce Bebo and Kristine Werner Ozug https://realtalkms.com/422 WATCH: The RealTalk MS ECTRIMS Extra Conversations video playlist on YouTube https://realtalkms.com/ectrims2025 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 425 Guests: Dr. Bruce Bebo Privacy Policy

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8009 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/37272512/ Plain Language Summary of the KarMMa-3 Study of Ide-cel or Standard of Care Regimens in People With Relapsed or Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38651976/ CAR T-Cell Therapy Toxicity https://www.ncbi.nlm.nih.gov/books/NBK592426/ Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience https://pubmed.ncbi.nlm.nih.gov/28205024/ Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-Cell Therapy https://pubmed.ncbi.nlm.nih.gov/38838226/ Long-Acting Granulocyte Colony-Stimulating Factor in Primary Prophylaxis of Early Infection in Patients With Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35064823/ Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37244325/ Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/38660139/ FDA Eliminates REMS for Approved CAR T-Cell Therapies https://www.aabb.org/news-resources/news/article/2025/06/30/fda-eliminates-rems-for-approved-car-t-cell-therapies

“El poder se ejerce con humildad”, afirma Sheinbaum Lluvias colapsan puente en Veracruz; afectan a ocho comunidadesEl café no da energía, sólo oculta el cansancio: expertosMás información en nuestro podcast

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

Olá, ouvintes! Neste novo episódio do Abrale Cast, entrevistamos o Dr. Renato Cunha, médico hematologista, pesquisador, líder da terapia celular do Grupo Oncoclínicas e professor da UNIFESP (Universidade Federal de São Paulo). Falamos sobre como as terapias celulares funcionam, além de tópicos como o CAR-T CELL e transplante de medula óssea. Vem conferir!

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

In this week's episode we'll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.Featured Articles:Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesDevelopment of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaDNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

Send us a textBone Marrow Transplant (BMT) and CAR T-cell therapy are evolving fast—are you keeping up? In this episode of TheOncoPT Podcast, Dr. Adam Matichak returns to share the latest updates on these groundbreaking treatments and what they mean for your OncoPT practice.You'll learn how CAR T-cell therapy is expanding, why mobility strategies matter more than ever, and how to use vital signs to guide your treatment decisions. Plus, we'll explore how you can advocate for rehab's role in oncology, prepare patients for complex treatments like BMT and CAR T, and find the resources you need to stay ahead in this rapidly changing field.Whether you're new to cancer rehab or a seasoned pro, this conversation will give you practical tools to treat your patients undergoing BMT and/or CAR T-cell therapy. Listen now!Listen to Adam's previous episodes:Ep. 204 - How to not feel lost with BMTsEp. 221 - Here's How to Treat Patients Undergoing CAR T-Cell TherapyGrab your free Ultimate Oncology Specialist Study Guide!Preparing for the ABPTS Oncology Specialist Certification Exam is one of the best ways to become an expert OncoPT.My new Ultimate Oncology Specialist Study Guide will help you start your exam prep on the right foot, so you can prepare for success & treat your patients like an expert.Grab your FREE study guide now! Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications  

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

In this week's episode we'll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors.Featured Articles: Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyMass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy inmultiple myelomaIn vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individualsMolecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLCD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Sixty patients with the rare non-Hodgkin Lymphoma blood cancer, will be given CAR-T Cell therapy which reprogrammes their immune cells to recognise and kill cancer cells. Cancer patient David Down spoke to Ingrid Hipkiss.

In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential of recombinant IL-1 receptor antagonist, anakinra, in a murine model of thrombotic thrombocytopenic purpura—an uncommon but potentially fatal disorder with limited therapeutic options. Finally, we'll learn about CAR T-cell therapy outcomes by race and ethnicity in large B-cell lymphoma. Non-Hispanic Black patients had lower rates of response and progression-free survival in axi-cel clinical trials and real-world data, raising awareness and giving further insights into potential inequitable access to care.Featured Articles:GM-CSF receptor expression determines opposing innate memory phenotypes at different stages of myelopoiesis Mortality, cardiac and cerebral damage reduction by IL-1 inhibition in a murine model of TTP Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity 

By now, you likely have heard about CAR-T Cell therapy, but what exactly is it? Today, we dive headlong into this topic with Dr. Max Konig. We cover how this therapy works, how CAR-T Cells are made and administered to patients. We discuss the risks associated with this type of therapy, the side effects and their management. Lastly, we'll discuss the rheumatic diseases amenable to CAR-T therapy, those that are not, the costs and ethics involved and what the future may hold for it in rheumatology. Enjoy! 

As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy.   “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD   Guest:  David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA   This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma.   Additional Reading/Sources ACCC Oncology Issues Article If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology

In this episode, Carl June, MD, pioneering immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Together, they discuss Carl's work on CAR T, a remarkable story of the first use of CAR T in a pediatric patient, and Carl's take on where oncology treatments are headed next.Though this episode was originally published in September 2023, back when we were called Bio Eats World, we're republishing it  during this year's ASGCT conference, where the latest advances in cell and gene therapy—like what Carl describes—are shared and discussed.

Neste episódio, Renata Capucci e Maria Scodeler recebem o doutor Vanderson Rocha, professor da USP, e Paulo Peregrino, publicitário em remissão do câncer graças ao tratamento Car-T Cell. Eles falam sobre a terapia promissora que já começou a dar resultados no Brasil.

CAR-T cells, used to treat cancer in some people, are now being investigated by the US Food and Drug Administration for possibly causing additional cancers. Kimmel Cancer Center director William Nelson at Johns Hopkins explains why there's a concern. Nelson: … Why are CAR-T cell therapies being investigated by the FDA? Elizabeth Tracey reports Read More »

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy.   “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD   Guest:  David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA   This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma.   Additional Reading/Sources If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology

Umoja Biopharma's CEO, Andy Scharenberg, M.D., joins Cell & Gene: The Podcast's Erin Harris to discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics. They discuss The Climb, or The Colorado Laboratory and Innovation Manufacturing Building, which is Umoja's lentiviral vector development and manufacturing facility. They also cover recent progress in lentiviral vector manufacturing.